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Abbreviations 
AKI   -   Acute kidney injury 
CIT   -   Cold ischaemia time 
COD   -   Cause of death 
DAKT   -   Dual adult kidney transplant 
DMII   -   Diabetes mellitus type 2 
DBD   -   Donation after brain death 
DCD   -   Donation after circulatory death 
DGF   -   Delayed graft function 
eGFR   -   Estimated glomerular filtration rate 
EVNP   -    Ex vivo normothermic perfusion 
HBI   -   Hypoxic brain injury 
HD   -   Haemodialysis 
HTN   -   Hypertension 
ICH   -   Intracranial haemorrhage 
IHD   -   Ischaemic heart disease 
IQR   -   Interquartile range 
MDRD  -   Modification of diet in renal disease 
NHSBT  -   National Health Service Blood and Transplant 
PD   -   Peritoneal dialysis 
PMH   -   Past medical history 
RBFi   -   Renal blood flow index 
SD   -   Standard deviation 
SPK   -   Simultaneous pancreas and kidney 
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TMA   -   Thrombotic microangiopathy 
UO   -   Urine output 
UTI   -   Urinary tract infection 
UK   -   United Kingdom 
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Abstract 
Warm machine perfusion technologies such as ex vivo normothermic perfusion (EVNP) are a 
promising means of organ preservation, assessment, and pre-conditioning prior to transplantation. 
The widespread use of EVNP in deceased donor kidney transplantation will require uptake in other 
units, but previous reports have not addressed how centres outside the originating unit might 
implement this new technique. We describe our combined approach to setting up a clinical EVNP 
service in two UK centres.  Learning points and processes are outlined and discussed, including 
the need for robust protocols, training and staffing issues, and the need for a multidisciplinary 
approach. Our initial clinical experience is discussed, including the first reported uses of EVNP for 
dual kidney transplantation, for multi-organ transplantation, and for assessment of segmental 
parenchymal perfusion defects. Clinical outcomes of 12 deceased donor kidneys that underwent 
EVNP are described, along with the first analysis of outcomes from paired kidneys that had 
undergone static cold storage only. It is anticipated that this report will encourage the wider 
adoption of EVNP at other kidney transplant centres.    
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Introduction 
The United Kingdom (UK) has seen significant improvements in deceased donor kidney 
transplantation over the past decade, with an increase in the number of deceased donors, especially 
donation after circulatory death (DCD) donors, and rising graft survival rates1. However, there are 
on-going issues in UK kidney transplantation that remain a cause for concern. Worldwide, many 
other countries face similar challenges. 
 
The average age and co-morbidities of deceased kidney donors are increasing1, and there still 
remains a disparity between the number of organs available from deceased donors and the number 
of patients on the transplant waiting list. This has cost implications, as there is a significant financial 
benefit associated with a patient receiving a transplant as opposed to continuing dialysis2. 
Furthermore, although kidney transplants from DCD donors have equivalent graft survival to those 
from donation after brain death (DBD) donors in the UK3-5, transplants from DCD donors have a 
much higher rate of delayed graft function (DGF), and a higher rate of organ discard6.  
 
Warm organ perfusion technologies such as ex vivo normothermic perfusion (EVNP) may be able 
to successfully address some of these concerns. EVNP is a technique using paediatric 
cardiopulmonary bypass technology enabling the perfusion of an organ with a warm, oxygenated, 
erythrocyte-based solution prior to transplantation7. Studies suggest that EVNP reduces DGF in 
extended criteria donor kidneys when compared to historical controls preserved using cold storage 
alone8. Furthermore, the Cambridge group has reported the use of EVNP in successfully 
transplanting human kidneys that were deemed untransplantable and declined by all UK transplant 
units9. EVNP may therefore be able to reduce the rate of deceased donor kidneys that are 
unnecessarily discarded6,10. However, EVNP is a technically complex procedure, and reports have 
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been published from only two groups to date9. Like any new innovation in surgery, it is essential 
that novel perfusion technologies are widely translatable to other units. 
 
The aims of this study are threefold. First, to present the combined early clinical outcomes of 
kidneys transplanted using EVNP from two centres new to the technique, including the only 
reported analysis of outcomes of paired kidneys from the same donor transplanted without EVNP. 
Second, to detail the key learning points for centres considering implementation of clinical EVNP, 
focussing on organisational and technical issues. Finally, the use of EVNP for hitherto novel 
indications is also described. The authors anticipate that this report will encourage the adoption of 
EVNP at other kidney transplant centres. 
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Methods 
The evolution of a clinical EVNP programme at two units (Guy’s Hospital, London (centre 1), and 
Freeman Hospital, Newcastle (centre 2)) in December 2015 is described. Both centres took similar 
approaches to implementing EVNP based on mentorship, step-wise training, and frequent 
evaluation. The timing of the steps below varied slightly due to variances in progression through 
local governance pathways. Both EVNP services had similar staffing led by a consultant transplant 
surgeon, with two or three surgical trainees providing additional support.  
 
Clinical governance  
Nationally, the NHS Blood and Transplant (NHSBT) Kidney Advisory Group11 discussed the 
implications of EVNP expansion, and the consequences of a kidney that had undergone EVNP 
being subsequently declined for implantation and then offered to a non-EVNP centre. The Kidney 
Advisory Group approved the use of EVNP kidneys being offered back to the national transplant 
pool, if needed. 
 
At hospital level, both new centres obtained local clinical governance approval for the use of EVNP 
via novel procedures committees. For both centres, advice was sought from local hospital 
departments including haematology (to approve the use of packed red blood cells from the blood 
bank), microbiology (to assess the risk of potential infection of the kidney during EVNP)12-15, 
medical physics (to test and approve EVNP equipment), and operating theatre and anaesthetic staff 
(to provide the environment for clinical EVNP).   
 
Transplant surgical colleagues within each department were consulted as to the potential clinical 
value of the new EVNP services. Demonstrations of the EVNP machine were undertaken for 
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colleagues in order for them to better understand the technique. Both centres engaged with local 
patient groups to raise awareness of EVNP, and the indications for its use. EVNP was only used 
after a discussion of the perceived risks and benefits was had with each patient and written consent 
was given. Patient information sheets were given to each patient prior to consent discussions 
(supplementary data; figure 1).  
 
EVNP training 
Both new centres first observed porcine kidneys undergoing EVNP at the Cambridge mentor centre. 
This involved observing the machine set up, drug preparation and administration, renal artery and 
vein cannulation, normothermic perfusion of the kidney, and vessel decannulation. Written EVNP 
protocols were scrutinised and learnt by both centres and members of the EVNP perfusion teams 
underwent dedicated supervised training days at the mentor centre. This involved a structured 
learning programme with progressive steps evaluated at each stage using a proforma. The 
programme covered knowledge of EVNP components, system set-up, priming, kidney cannulation, 
perfusion, decannulation and cold perfusion, disposal of consumables, data recording, and use of a 
kidney assessment tool using EVNP16. Staff from both centres were assessed against the proforma 
and, once deemed competent, were formally signed off as capable of independently performing the 
EVNP technique. 
 
Training with untransplantable human kidneys 
Before starting their clinical EVNP programmes, both centres performed EVNP on five human 
kidneys deemed unsuitable for transplantation that had been offered for research. This step enabled 
a safety check of the machine and EVNP process. Approval was obtained through NHSBT and 
local research ethics committees. During this phase, it became apparent that members of the EVNP 
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team should focus on specific tasks to ensure timely machine set-up and organ perfusion. The lead 
EVNP surgeon had responsibility for kidney bench work, vessel cannulation and decannulation, 
while the surgical trainees focussed on EVNP machine preparation and monitoring. An 
experienced member of the mentor centre EVNP team (SH) was present for warm perfusion of the 
first discarded kidney at both centres, to check competencies and offer advice. For each subsequent 
kidney EVNP, SH was available via telephone and video-teleconferencing facilities to advise and 
support, as the need arose. After five discarded kidney perfusions at each centre, SH discussed any 
learning points with the EVNP lead from each centre (CW and CC) before agreeing that clinical 
EVNP programmes could start. These programmes were in place before a randomised controlled 
trial of EVNP was initiated7. 
 
Indications for clinical EVNP use 
Indications for EVNP of a deceased donor kidney prior to transplantation were: significant donor 
risk factors for DGF (e.g. expanded criteria donor, DCD donor, or donor acute kidney injury (Acute 
Kidney Injury Network stage 2 or 317)); or the need for viability assessment (e.g. sub-optimal cold 
flush of the kidney). Contraindications to the use of EVNP were: kidneys enrolled in a research 
study; injury or pathology not considered reversible by EVNP; multiple arteries not amenable to 
cannulation. 
 
EVNP technique  
The EVNP technique has been reported elsewhere8,18. Briefly, the EVNP circuit was based on 
commercially available paediatric cardiopulmonary bypass technology (Bio-Console 560, 
Medtronic, Watford, UK), with a heater (Chalice Medical, Nottinghamshire, UK), a combined heat 
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exchanger / oxygenator, and tubing (both Medtronic, Watford, UK). Hardware also included a flow 
transducer, temperature probe, and fluid infusion pumps (Figure 1). The renal artery and vein were 
cannulated and secured in place with 2/0 polyglactin ligatures. The kidney was placed in a sterile 
stainless steel chamber and perfused with heparinised red cell-based perfusate consisting of one 
unit of O Rhesus negative packed cells, 250 mL of Ringer’s lactate, nutrients, dexamethasone, 
mannitol, insulin, prostacyclin, and bicarbonate.  
The kidneys were perfused for 60 minutes at a pressure of 75 mmHg, and at 36oC. Ringer’s lactate 
replaced urine output mL for mL. During EVNP, perfusion pressure, urine output, renal blood flow, 
and perfusate temperature were recorded. Renal blood flow index (mL/min/100g) was calculated 
using the weight of the kidney before perfusion. Intra-renal resistance was calculated from the renal 
blood flow index and perfusate pressure. Arterial and venous blood gas samples were taken before 
perfusion, at 30 min and 60 min perfusion to ensure physiological conditions and to measure tissue 
oxygen consumption. 
Each kidney was scored according to macroscopic appearance (1=excellent, 2=moderate/patchy, 
3=poor), renal blood flow index (<50 mL/min/100g=1) and urine output (<43 mL/hr=1). This gave 
each kidney a total quality score of 1-5 (1-2=good; 3-4=moderate; 5=poor)16.  If the kidneys scored 
3 or less, they would be considered potentially suitable for transplantation after consultation with 
the on-call surgeon, with whom the final decision regarding implantation would lie.  
Organ safety during EVNP was a prime concern. Before the clinical EVNP programmes started, 
both centres agreed that the occurrence of a major technical event would lead to a pause of their 
EVNP programme to enable discussion with the mentor centre and training, as needed. Major 
technical events were defined as any one of the following: unexpected decannulation of the kidney; 
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major leaks of perfusate from the circuit requiring use of additional packed red blood cells; and 
equipment malfunction leading to the possibility of organ hypo-perfusion. These were recorded 
prospectively. 
 
Clinical data collection and analysis 
Donor and recipient characteristics, and clinical outcome data, were recorded prospectively from 
kidneys that were transplanted after EVNP, and from paired kidneys from the same donor that had 
undergone static cold storage only. Kidneys undergoing EVNP from April 2016 to July 2017 were 
included; study follow-up ended on 1 May 2018. 
Following transplantation, recipient serum creatinine and estimated glomerular filtration rate (four-
variable Modification of Diet in Renal Disease (MDRD)) were recorded at one week, and one, 
three, six, and 12 months. If EVNP was associated with bacterial contamination of the kidney, it 
was felt that this would most likely manifest as an infected collection around the graft (i.e. an 
organ/space surgical site infection19). Data on infected perinephric collections within three months 
of transplantation were recorded prospectively. 
Delayed graft function (DGF) was defined as the need for dialysis, for any cause, in the first 7 days 
post-transplantation20. Duration of DGF was defined as the number of days from transplantation to 
the last day of dialysis. Primary non-function was defined as failure of the graft to ever function 
following transplantation, regardless of cause. Graft failure was defined as return to dialysis or 
graft nephrectomy, whichever occurred first, and was censored for death. Cold ischaemia time 
(CIT) was defined as the period from the start of cold perfusion in the donor to reperfusion with 
blood within the recipient (i.e. including the EVNP duration). 
Where one kidney from a donor was implanted after EVNP and the paired kidney was transplanted 
after static cold storage only, characteristics and post-transplant outcomes were compared. Groups 
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were compared using Fisher’s exact and chi-squared tests for nominal data, the Mann-Whitney test 
for ordinal or non-parametric continuous data, and Student’s t-test for parametric continuous data.   
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Results 
Insights during the learning phase of EVNP using discarded kidneys 
Between December 2015 and February 2016, both centres underwent the learning phase of EVNP 
using five discarded kidneys. Both centres reported no major technical events during EVNP in this 
phase. During this learning process, three practical issues became apparent.  
Firstly, three personnel were ideally required during the EVNP. Two scrubbed surgeons (one 
trained in EVNP) were needed at kidney cannulation and subsequently at decannulation and cold 
flushing. The third (unscrubbed) team member operated the machine, administered drugs and fluids, 
and recorded data. Secondly, set up of the EVNP machine and circuit took longer than initially 
anticipated, with average times of 90 minutes. Finally, preparation time was further prolonged if 
the kidney had multiple vessels arising from the aortic patch. This required end-to-side anastomosis 
of the smaller artery to the main artery to create a single orifice for cannulation.  Use of the right 
kidney for EVNP required preparation of the attached inferior vena cava with ligation of side 
branches and oversewing of the infrahepatic inferior vena cava and left renal vein orifices. Hence, 
this initial phase was a critical learning process, not only in the specific practical aspects of 
performing EVNP but also in appreciating the need to complete the organ preparation, machine 
set-up, and organ perfusion steps in a timely manner. 
During this phase, a checklist was adopted by centre 1, with the aim of decreasing machine set-up 
times, and reducing the risk of technical events (Supplementary data, Figure 2). 
 
Clinical EVNP experience 
Between 1 March 2016 to 31 July 2017, EVNP was performed on 14 kidneys from 12 donors (11 
kidneys in centre 1, three kidneys in centre 2). Of the 14 kidneys that underwent EVNP, 12 organs 
were implanted into 10 recipients. Two pairs of kidneys were implanted as dual grafts and one 
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kidney was implanted simultaneously with a pancreas. The remaining seven kidneys were 
transplanted as single allografts (Table 1).  
Two kidneys from two different donors were not implanted following EVNP; the first kidney 
(organ 6, Table 1) scored 3 on EVNP and was deemed unsuitable for the intended recipient (the 
contralateral non-EVNP kidney was not implanted for the same reason). The second kidney (organ 
8, Table 1) was not transplanted as the recipient had a significant anaesthetic complication 
requiring the transplant to be cancelled. This kidney was intended to be implanted as a dual graft, 
but only one kidney had completed EVNP before the transplant was unexpectedly cancelled. These 
two kidneys were subsequently offered to other centres but were declined by all centres due to 
prolonged CIT and were discarded.  
 
Table 1 shows the donor and recipient characteristics for each kidney that underwent EVNP. 
Median (IQR) donor age was 65 (48-69) years, and nine (64%) were DCD donors. The indications 
for EVNP were viability assessment (n = 6) and/or reduction of DGF (n = 11). Median (IQR) 
recipient age was 54 (39-60) years.  
 
Organ assessment parameters on EVNP, and subsequent CITs are shown in Table 2. Kidneys 
underwent EVNP for a median (IQR) duration of 60 (59-60) minutes, and the median (range) 
EVNP viability score was 1 (1-3). Oxygen consumption was measured in 5 kidneys. Median (IQR) 
oxygen consumption was 59.6 (40.4-93.8) mL/min/g. Renal blood flow index was measured 
throughout perfusion and showed a gradual increase during EVNP (Figure 2). Mean (SD) CIT was 
14:45 (2:27) hours:minutes for kidneys implanted as single grafts. The mean (SD) time from the 
end of EVNP to re-perfusion of single kidney-only transplants in the recipient was 3:24 (2:49) 
hours:minutes. Centre 1 did not to begin the recipient operation until the organ was fully assessed 
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during EVNP (as the majority were performed for viability assessment) and therefore had a 
relatively longer CIT following EVNP (mean (SD) 309 (151) minutes). Centre 2 began the 
recipient operation during organ perfusion, leading to a shorter CIT following EVNP (mean (SD) 
65 (11) minutes). 
 
Additional learning points during early EVNP clinical experience 
Performing EVNP on kidneys for clinical transplantation provided additional learning points. In 
smaller theatres, it was challenging for EVNP to take place during the recipient’s operation. 
Another theatre was therefore required, limiting the ability to perform EVNP during working hours 
when theatre capacity was limited. In addition, two technical issues were encountered at centre 1. 
One kidney had an unplanned arterial decannulation, which was rectified within two minutes by 
re-cannulation. Subsequently, tying the ligature around the artery to another ligature around the 
proximal cannula prevented this from reoccurring. On another occasion, the kidney cradle venous 
outflow pipe became occluded due to an air lock, resulting in a depletion of the circulating volume, 
with subsequent organ hypoperfusion. The kidney underwent early decannulation after 45 minutes 
of EVNP and was then implanted. After this, the draining tube from the venous reservoir to the 
cradle was regularly checked and manipulated to improve drainage. Technical issues experienced 
during machine set-up, or organ perfusion, along with possible causes, are shown in Table 3.  
 
Recipient outcomes 
In the ten recipients that received kidneys that had undergone EVNP, there were no cases of 
primary non-function. Three patients experienced delayed graft function (30%), for between 5-8 
days duration. Median (IQR) inpatient stay was 10 (8-14) days. Patient and graft survival was 100% 
at one year, with median (IQR) eGFR of 52 (35-63) mL/min/1.73m2 at 6 months, and 53 (40-62) 
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mL/min/1.73m2 at 12 months. There were no serious adverse events attributable to EVNP in our 
patients. There was one instance of an infected deep perinephric collection following implantation 
of an EVNP kidney. However, this collection was originally sterile, but, following repeated 
percutaneous drainages, became secondarily infected. This was treated successfully with 
intravenous flucloxacillin. 
 
Post-transplant outcomes of single kidneys implanted after undergoing EVNP were compared with 
those of the non-EVNP contralateral kidney from the same donor (Tables 1 and 3). The pair of 
kidney 8 was not transplanted due to severe parenchymal retrieval damage, and therefore kidney 8 
was excluded from this analysis. There was no statistically significant difference in recipient 
demographics between the two recipient groups. The CIT was significantly longer in kidneys 
receiving EVNP compared to static cold storage (mean (SD) 843 (105) vs. 608 (167) minutes; 
p=0.011). There were no statistically significant differences in the rates of primary non-function or 
DGF between the two groups (p=1.00, p=0.56, respectively). Statistical analysis of DGF duration 
could not be performed, as there was only one episode of DGF in the EVNP group. There was no 
difference in graft function between the two groups at one week and one-, three-, six- and 12-
months post transplantation (p=63, p=0.58, p=0.71, p=0.74, p=0.22, respectively).  
 
Novel uses of EVNP 
EVNP in dual adult kidney transplantation (DAKT): Centre 1 performed the first reported cases 
of DAKT after sequential EVNP on both kidneys (kidneys 1 and 2, and 4 and 5 on Table 1). The 
first recipient had immediate graft function, with good graft function at 12 months post-transplant 
(creatinine 122 µmol/L, eGFR 53 mL/min/1.73m2). The second recipient received kidneys that had 
been declined by another unit due to sub-optimal cold flush. The kidneys perfused well on EVNP 
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with viability scores of 1 and 2, respectively. However, this recipient had DGF of 8 days duration, 
and kidney transplant biopsies at day 5 post-operatively demonstrated acute thrombotic 
microangiopathy (TMA). Blood tests were unable to identify any underlying causes for the TMA 
such antibody-mediated rejection, atypical haemolytic uraemic syndrome or procoagulant 
disorders. The patient was treated with plasma exchange and intravenous immunoglobulins. Repeat 
biopsy at day 12 post-transplantation showed resolution of TMA. Oral tacrolimus was continued 
as tacrolimus-related TMA was thought to be highly unlikely due to the early onset. The patient 
has poor graft function at 12 months post-transplantation (creatinine 340 µmol/L, eGFR 12 
mL/min/1.73m2) but remains dialysis-independent.  
 
EVNP in simultaneous kidney transplantation (SPK): Centre 1 also performed the first reported 
kidney EVNP before SPK transplantation (kidney 11, Table 1). The recipient had immediate graft 
function and good function at 6 months post-transplantation (creatinine 126 µmol/L, eGFR 44 
mL/min/1.73m2). Unfortunately, the patient developed post-transplant lymphoproliferative 
disorder four months post-operatively and is receiving chemotherapy. 
 
EVNP in the assessment of vascular injury: During procurement of a kidney from a 40 year-old 
DBD donor, the renal artery was incised 1 cm from the renal hilum. The renal artery was cut 
through 50% of its circumference at the bifurcation into segmental arteries (Figures 3a and 4b). 
Vascular reconstruction of the injury was not possible without ligation of one of the branches. 
However, the effect of ligating one of the branches on parenchymal and ureteric perfusion was not 
known. The decision was therefore made to ligate the branch, repair the injury and assess the 
perfusion deficit during EVNP. Therefore, one branch was ligated and the renal artery was 
reconstructed using 6-0 Prolene (Figure 3c). There was no significant bleeding from the repaired 
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vessels, and the renal parenchyma re-perfused well anteriorly (Figure 4a). There was a small 
perfusion deficit at the posterior-superior aspect of the kidney (Figures 4b and c), comprising <10% 
of the renal parenchyma.  The ureter was well perfused, and the kidney was transplanted (kidney 
10, Table 1). The recipient’s lowest creatinine was 222 µmol/L at four months post-transplant; 
deteriorated graft function led to a graft biopsy that showed recurrent membranous nephropathy.  
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Discussion 
EVNP is a promising technique that may enable deceased donor kidney to undergo pre-
conditioning and viability assessment. However, if the early potential of this technology is to be 
realised outside the originating centre, the technique will need to be readily translatable to other 
units. This multi-centre observational study details the key organisational issues of establishing a 
clinical EVNP service. A defined training pathway enabled clinical EVNP services in two UK 
centres to be established after a learning curve with five non-transplantable deceased donor kidneys. 
Technical challenges became apparent, but were readily overcome. Twelve kidneys were 
transplanted into 10 recipients after EVNP. The rate of DGF was 30%, with no complications 
attributable to the EVNP technique.  
 
The introduction of a clinical EVNP service requires a multimodal approach, including governance, 
logistical, and training considerations. Given that it was possible that organs would be declined for 
transplantation after undergoing EVNP, it was felt important that other centres in the UK were 
made aware of the implications of receiving such an organ. These discussions focussed on the 
potential loss of the aortic patch and shorter vessel length in the donor kidney due the need for 
EVNP cannulation insertion. Extensive discussions with local haematology departments were also 
needed to ensure that any units of packed red blood cells used during EVNP were attributed to the 
correct recipient, even if an organ was declined after EVNP and transported to another kidney 
transplant centre. 
 
EVNP logistical issues are challenging. The procedure is undertaken in theatre; ideally in the same 
theatre that the transplant will take place. The equipment and personnel needed for EVNP currently 
take up enough space to cause problems if simultaneous transplant surgery is undertaken in a small 
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theatre. Ideally, a dedicated perfusion theatre would be used, though it seems likely that further 
evidence of the benefit of EVNP will be required before most transplant units would consider such 
an investment of space and resources.  
 
The EVNP technique itself was readily learnt, aided by a structured learning approach and formal 
assessment criteria. It was felt that this strategy, along with EVNP of discarded human kidneys, 
provided sufficient capability for the clinical programme to be initiated. EVNP remains a complex 
technique, however, and even with this experience, it was inevitable that some technical issues 
would arise. A close relationship with the mentor centre was essential, along with ready access to 
out-of-hours expertise. The use of a checklist reduced inefficiencies in the machine set-up process, 
and provided reassurance that essential steps had been completed. Even with these systems in place, 
it is likely that only larger kidney transplant units will be able to staff an EVNP service that uses 
current technology. These considerations may mean that smaller centres may wish to transport 
selected deceased donor kidneys to regional ‘perfusion hubs’ for EVNP to be undertaken, before 
being transported back to the referring centre 21. 
 
In order to reduce the risk of significant bleeding from the kidney at the start of EVNP, back-table 
preparation must be meticulous. Retrieving the right kidney with a tube of IVC enabled cannulation 
of the IVC at the confluence, preserving the length of the venous outflow. Arterial cannulation was 
complex if there were multiple renal arteries. The implanting surgeon must be willing to accept a 
kidney with no aortic patch, as the arterial cannula ligature site is routinely excised after EVNP. 
The introduction of effective patch clamps may avoid this issue, in future.  
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At present, the main indications for EVNP are to attempt to reduce DGF, and to assess organ 
viability (e.g. those with poor cold perfusate flush). Kidneys from donors with significant AKI may 
benefit from EVNP for both of the above indications. DGF occurs in approximately 25% of kidney 
transplants from DBD donors and approximately 50% of DCD kidney transplants5. DGF is 
associated with prolonged length of stay and the need for graft biopsies. In DBD kidney 
transplantation, DGF is also associated with acute rejection22, chronic allograft dysfunction23 and 
graft loss22,24. A randomised controlled trial of EVNP use in DCD kidney transplantation is 
currently underway in the UK7, and results are awaited with interest. 
 
In this series, 30% of patients had DGF, despite the use of organs from older, predominantly DCD, 
donors. There were no instances of graft or patient loss within the follow-up period, and early graft 
function was good. There were seven donors where one kidney received static cold storage and 
EVNP, and the other received static cold storage alone. Although there was a trend towards lower 
DGF and primary non-function rates in the EVNP group, this did not reach statistical significance. 
These results are encouraging, however, and are the first paired analyses to be published8. 
Importantly, there were no complications in our series that were attributable to EVNP (e.g. infected 
perinephric collections, vascular thrombosis). A previous study has shown that a significant 
proportion of cultures taken from warm perfusate during EVNP grew bacteria, though these are of 
doubtful clinical significance12,15. Given uncertainties about appropriate doses, and the underlying 
rationale, antibiotics are not given during EVNP.  
 
Other clinical scenarios where EVNP may be beneficial are described above, for the first time. 
DAKT and SPK transplants are prolonged operations, often in recipients with multiple co-
morbidities. Avoidance of DGF makes post-operative fluid management more straightforward, and 
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might avoid the associated adverse cardiovascular and tissue healing implications associated poor 
graft function. Primary renal graft function in the SPK recipient was surprising, given the donor 
history of significant AKI, and suggests that EVNP was beneficial in this case. We note that the 
second DAKT recipient developed TMA, with no apparent underlying cause. To the best of our 
knowledge, this has not been reported in any other recipient of a kidney that has undergone EVNP, 
and therefore it would appear unlikely that the EVNP technique was a causative factor. 
 
This study also demonstrates the potential for EVNP to assess vascular injuries and perfusion 
deficits. Injury to the kidney occurs in 7.1% of procurement procedures in the UK25 and often 
results in organ discard. Polar arteries appear to be at greatest risk of vascular injury26. This novel 
indication for EVNP has the potential to increase the donor pool, as there are currently no 
established means of assessing organ damage beyond checking for leaks using cold fluid flush. A 
significant perfusion deficit or compromise of the ureteric blood supply27 would have allowed the 
surgeon to make an informed decision whether to proceed with implantation or not. Assessment 
during EVNP also enables the integrity of the vascular repair to be examined. Other novel 
indications for EVNP are under investigation, including its use in prolonged preservation28, 
manipulation of organ immunogenicity29-32, and delivery of pharmacological33-38 or temperature-
dependent interventions (e.g. cellular therapies39).  
 
We acknowledge the weaknesses of this study. Whilst we have detailed the process necessary for 
two centres to establish EVNP, these may not fully reflect processes outside of the UK. As with 
any early experience, patient numbers were small, and larger groups and longer follow-up may be 
necessary to detect events in survival analyses.  
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This study has demonstrated the challenges of introducing a new perfusion technology and has 
described a pathway that we hope other kidney transplant units will find valuable. EVNP is a 
complex technique, but can rapidly be learnt if appropriate training and mentoring is available from 
an experienced centre. Early experiences suggest that EVNP is a safe technique, and that graft and 
patient outcomes are acceptable. The indications for kidney EVNP are expanding, and EVNP is 
likely to be an increasingly useful tool in the transplant surgeon’s armamentarium. 
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Figure 1: Ex vivo normothermic perfusion (EVNP) circuit components. This figure shows 
the schematic arrangement of the main components of the EVNP perfusion system with the 
arrows indicating direction of blood flow. 
  
 
 
 
 
 
 
 
Figure 2: Mean (SD) renal blood flow index during ex vivo normothermic perfusion (n=14 
kidneys) 
 
 
  
 
Figure 3: (a) Retrieval injury of the right renal artery. 50% of the artery circumference ligated at the bifurcation. (b) Diagram of renal artery injury (c) Repair 
of the right renal artery: one branch ligated, with primary closure of the remaining vessel 
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Figure 4: (a) Anterior aspect of the kidney during EVNP: global perfusion (b) Posterior aspect of the kidney during EVNP: upper pole perfusion defect of the 
renal parenchyma detected (<10%) marked with black arrow. (c) Posterior aspect of the kidney after implantation into the recipient: upper pole perfusion 
defect marked with black arrow. 
 
 
 
 
  
Organ 
number 
Donor 
type 
Indication
(s) for 
EVNP 
Donor 
age / 
sex 
Donor 
COD 
Donor 
PMH 
Organ 
side, 
findings 
Visual 
score  
(1-3) 
RBFi 
(ml/min
/100g) 
UO 
(ml/hr) 
EVNP 
score 
(1-5) 
O2 
consu-
mption 
(ml/min
/g) 
Time 
on 
EVNP 
(min) 
CIT 
(hr:min) 
Recipient 
number 
and 
transplant 
type 
Recipient 
age / sex 
Dialysis 
status 
DGF 
duration 
(days) 
Paired 
analysis 
1 
DCD 
Viability 
assessment 
and 
reduction 
of DGF 
69F 
HBI 
after 
cardiac 
arrest 
Terminal 
creatinine 
202 
umol/L 
(no 
baseline) 
R 1 81 150 1 Not recorded 68 20:18 
1 – Dual 60M HD 0 
No 
2 L 2 23 50 2 Not recorded 60 20:48 No 
3 DCD Reduction of DGF 66M 
Pneum
onia 
and 
resp. 
failure 
COPD R 1 59 80 1 Not recorded 55 13:40 2 – Single 54F PD 0 Yes 
4 
DCD 
Viability 
assessment 
and 
reduction 
of DGF 
66F ICH 
HTN (2 
agents), 
DMII, 
meningio
ma 
L, poor 
cold 
flush 
2 46 120 2 Not recorded 65 22:30 
3 – Dual 58F HD 8 
No 
5 
R, poor 
cold 
flush 
1 63 160 1 Not recorded 53 24:00 No 
6 DCD Reduction of DGF 71M 
HBI 
after 
cardiac 
arrest 
HTN (2 
agents) R 3 29 55 3 26.6 60 
Organ not implanted 
(EVNP score 3) No 
7 DBD 
Viability 
assessment 
and 
reduction 
of DGF 
17F 
HBI 
after 
cardiac 
arrest 
Asthma, 
bronchie-
ctasis 
AKIN 
stage 2 
R 2 120 25 2 112.1 60 14:00 4 - Single 28M HD 0 Yes 
8 DBD 
Viability 
assessment 
and 
reduction 
of DGF 
55F 
HBI 
after 
cardiac 
arrest 
AKIN 
stage 3, 
IHD 
R 3 50 15 3 Not recorded 60 18:44 5 - Single 54M PD 5 No 
9 DBD Reduction of DGF 76F ICH HTN L 1 97 190 1 54.1 60 
 Intended as a DAKT. 
Organ not implanted (named recipient had significant 
anaesthetic complication) 
No 
10 DBD 
Viability 
assessment 
– injury to 
renal 
artery 
40F 
HBI 
after 
cardiac 
arrest 
None R 1 83 83 2 59.6 60 16:21 6 – Single 42M HD 5 Yes 
11 DBD 
Viability 
assessment 
and 
reduction 
of DGF 
21M Trauma AKIN stage 3 L 1 183 212 1 59.6 60 13:11 7 - SPK 29F HD 0 Yes 
12* DCD Reduction of DGF 53F ICH None L 1 89 555 1 
Not 
recorded 60 10:52 8- Single 61M 
Pre-
emptive 0 Yes 
13* DCD Reduction of DGF 51M ICH 
HTN, 
UTIs,  L 1 112 210 1 
Not 
recorded 60 14:09 9 - Single 48M HD 0 Yes 
14* DCD Reduction of DGF 64F ICH None L 1 76 360 1 
Not 
recorded 60 13:35 10 - Single 64M HD 0 Yes 
* Kidneys implanted by centre 2. 
Acute kidney injury (AKI) categorized according to the Acute Kidney Injury Network (AKIN) stage, cold ischemia time (CIT), cause of death (COD), 
donation after brain death (DBD), Dual adult kidney transplant (DAKT), donation after circulatory death (DCD), delayed graft function (DGF), diabetes 
mellitus type 2 (DMII), ex vivo normothermic perfusion (EVNP), hypoxic brain injury (HBI) hemodialysis (HD), hypertension (HTN), intracranial 
hemorrhage (ICH), ischemic heart disease (IHD), peritoneal dialysis (PD), past medical history (PMH), renal blood flow index (RBFi), simultaneous pancreas 
kidney (SPK), urine output (UO), urinary tract infection (UTI) 
 
Table 1. Donor, recipient, EVNP, and clinical characteristics for each kidney undergoing ex vivo normothermic perfusion (EVNP) in both centres 
 
  
Abnormal findings Possible causes 
Reduced organ perfusion 
• Air lock (bubble) within arterial cannula 
• Blood pooling in cradle, with reduced 
flow back into venous reservoir 
• High intra-renal (parenchymal) 
resistance 
Accidental arterial decannulation 
• Loosely tied ligatures between cannula 
and vessel 
• Excessive traction on cannula 
Abnormal pressure readings 
• Leaks within the pressure line system 
• Incomplete de-airing of centrifugal pump 
chamber 
• Manometer improperly calibrated prior 
to organ perfusion start 
Perfusate temperature <36oC 
• High intra-renal resistance with low 
perfusate flow, leading to excessive 
cooling 
• Heat exchanger fluid not circulating 
 
Table 2: Abnormal findings during ex vivo normothermic perfusion set-up and/or organ perfusion, and possible causes. 
 
 
 
 
 
 
  
 Variable EVNP kidneys n=7 
Static cold storage 
n=7 p value 
Recipient age (years) 48 (29-61) 57 (31-61) 1.00† 
Recipient male sex 5 (71%) 5 (71%) 1.00* 
Pre-transplant mode of dialysis 
    None 
    Haemodialysis 
    Peritoneal dialysis 
 
1 (%) 
5 (%) 
1 (%) 
 
0 (0%) 
5 (60%) 
2 (40%) 
0.51‡ 
Cold ischaemia time (minutes) 838 (105) 608 (167) 0.01§ 
Primary non-function 0 (0%) 1 (20%) 1.00* 
Delayed graft function 1 (14%) 3 (43%) 0.56* 
Death-censored graft survival at 1 year 100% 86% 0.31¶ 
1 week eGFR (mL/min/1.73m2) 24 (18) 30 (31) 0.63† 
1 month eGFR (mL/min/1.73m2) 47 (14) 53 (24) 0.58† 
3 month eGFR (mL/min/1.73m2) 46 (14) 50 (20) 0.71† 
6 month eGFR (mL/min/1.73m2) 51 (14) 48 (19) 0.74† 
12 month eGFR (mL/min/1.73m2) 59 (15) 53 (21) 0.64† 
 
Data expressed as mean (SD), median (IQR), number (%) 
*Fisher’s exact test, †independent t-test, ‡Chi-squared test, §Mann-Whitney U test, ¶Log rank. Estimated glomerular filtration rate (eGFR) analysis excludes 
graft failure 
 
Table 3: Paired analysis between kidneys undergoing ex vivo normothermic perfusion (EVNP) and those undergoing static cold storage only 
Supplementary data 
 
 
 
Warm blood flow before kidney transplantation (EVNP)  
 
We would like to inform you about a new treatment that may help to make your transplanted 
kidney work more quickly. This leaflet explains more about warm blood flow (ex vivo 
normothermic perfusion or EVNP), including the benefits, risks and any alternatives, and what you 
can expect when you come to hospital.  
 
The information will help you decide whether this treatment is right for you. If you have any further 
questions or concerns, please contact us using the contact details on the back of this leaflet.  
 
What happens to a donor kidney before it is transplanted?  
 
When a kidney is removed from a deceased donor the blood is flushed out of it with a cold liquid and then 
it is stored in a box of ice until it is ready to be transplanted. This process is called ‘static cold storage’. 
Static cold storage has been used in kidney transplantation for more than 30 years, and is both simple and 
effective. It is therefore the standard procedure used in most transplant centres around the world.  
 
Static cold storage, however, does not preserve the kidney perfectly, and there is still some damage to the 
kidney that gets worse the longer the kidney is stored. This may mean that the kidney takes longer to 
‘wake up’ and start working after the transplant. Around half of patients who receive a kidney transplant 
from a deceased donor may need to wait a while for the kidney to start working. This can take a few days 
or sometimes a few weeks.  
 
What is warm blood flow (EVNP)?  
An alternative to static cold storage is to pump warm blood through the kidney for about an hour before 
it is transplanted into you. This procedure uses a machine similar to the one used during open-heart surgery 
often referred to as a ‘bypass machine’. The bypass machine looks like a small dialysis machine and 
consists of a pump, tubing, and some equipment to warm the blood and expose it to oxygen. The blood 
that is used is stored blood that has been previously donated by blood donors. Once the process is finished, 
the blood is flushed out of the kidney. Every part of the machine that touches the kidney remains sterile. 
This process is called EVNP.  
 
The purpose of EVNP is to provide blood and oxygen to the kidney before it is transplanted into you. This 
allows the kidney to recover from some of the damage caused by cold storage.  
EVNP has been used successfully in Leicester, and the transplant team at Guy’s would like to introduce 
it here. Using EVNP in Leicester, only 1 out of 18 patients had transplanted kidneys that were slow to 
wake up and start working after the transplant. 
 
Why is this treatment being suggested for my kidney transplant?  
 
A patient with a kidney transplant that is slow to wake up needs dialysis until it starts to work. They may 
feel unwell due to build-up of toxins (poisons) in their body. These patients need regular ultrasound scans 
until the kidney starts working, and are likely to need one or more kidney biopsies (have tissue samples 
taken) to make sure that the kidney is not being rejected by their body. With any kidney biopsy there is a 
small risk of bleeding and of damage to the kidney. The biopsy procedure can also be uncomfortable, as 
the patient must remain lying flat for four to five hours afterwards. Patients with kidney transplants that 
are slow to wake up spend a longer time in hospital because of the need for extra ultrasound scans and 
biopsies.  
 
The expected benefit of EVNP is that it increases the chance that your kidney will work straight away 
after the transplant. This will avoid the need for extra ultrasound scans and kidney biopsies, and will help 
get you home from hospital more quickly.  
 
Sometimes EVNP is used to check that the blood flow through the kidney is good and to see if the kidney 
can make urine while it is attached to the EVNP machine. If the blood flow is good and the kidney makes 
urine while on the EVNP machine, this can give the transplant surgeons more confidence that the kidney 
is suitable for transplantation.  
The EVNP team will explain why they think that EVNP would be helpful to you and your kidney.  
 
What are the possible risks?  
All medical procedures carry some risk. It is possible that EVNP may introduce infection into the kidney, 
or damage it in some other way that we can’t yet predict. In the Leicester patients there were no unusual 
infections, bleeding problems, or damage to the kidneys resulting from the procedure.  
 
Are there any alternatives?  
If you decide not to allow your future kidney transplant to undergo EVNP it will be stored in the usual 
way in cold liquid in the icebox until your operation.  
 
Sometimes, EVNP might be used if the transplant surgeons are concerned about the chance of poor blood 
flow in the kidney after transplantation. If this is the reason for recommending EVNP, and you decide not 
to allow the kidney to undergo EVNP, there may be an increased risk of poor blood flow in the kidney. 
The transplant surgeon looking after you will tell you if they think that EVNP is needed, or if static cold 
storage is an acceptable option for your kidney.  
 
How many times has this been done at Guy’s before?  
 
This is a new treatment that we have introduced at Guy’s. We will tell you how many times EVNP has 
been used at Guy’s when we discuss the treatment with you and seek your consent 
Consent - asking for your consent  
 
We want to involve you in decisions about your care and treatment. If you decide to go ahead, you will 
be asked to sign a consent form. This states that you agree to have the treatment and you understand what 
it involves.  
 
If you would like more information about our consent process, please speak to a member of staff caring 
for you.  
 
What will happen next?  
 
The kidney will be attached to the EVNP machine for about an hour. The transplant surgery and the rest 
of your treatment after the transplant will be as usual, and you will not need any extra tests or extra clinic 
visits. The transplant team and Mr Callaghan will monitor you closely to detect any possible problems 
that might be due to the EVNP treatment.  
 
Your decision whether or not to choose this new treatment will not affect any other aspect of the care that 
you will receive before, during, or after the transplant. 
 
 
 
Figure 1 – Patient information sheet for ex vivo normothermic perfusion (EVNP). Logos and 
contact details have been removed from this document prior to submission to the journal. 
  
 
 
 
 
Before EVNP 
 
Before cannulation 
 
Before decannulation 
Have the team members introduced 
themselves and confirmed roles? 
Yes ☐ 
 
Confirm the correct organ for the 
correct recipient 
Yes ☐ 
N/A – no recipient selected yet ☐ 
 
Has the patient consented for EVNP? 
Yes ☐ 
N/A – no recipient selected yet ☐ 
 
Does the patient have any known drug 
allergies? 
No ☐ 
Yes ☐ ____________________ 
 
Does the patient have special blood 
requirements? 
No ☐ 
Yes ☐ Irradiated blood ☐ 
     CMV neg blood ☐ 
 
Is all equipment and disposables 
available for EVNP? 
Yes ☐ 
 
 
 
 
 
 
Has heparin 3000 units been given? 
Yes ☐ 
 
Are all bungs tight, with no leaks? 
Yes ☐ 
 
Is O2 flowing at the correct rate? 
Yes ☐ 
 
Is temperature within range? 
Yes ☐ 
 
Have blood transfusion checks been 
performed? 
Yes ☐ 
 
Has the pressure line been calibrated 
and the flow-probe in correct 
direction? 
Yes ☐ 
 
Are oxygen, haemoglobin, and pH 
within range on blood gas analysis? 
Yes ☐ 
 
Has the kidney been flushed with cold 
saline? 
Yes ☐ 
 
Is there cold preservation fluid, iv 
giving set, and a bowl of ice ready in 
case of rapid unplanned return to cold 
storage? 
Yes ☐ 
 
 
 
 
 
Have the intended blood samples 
been taken?  
Yes ☐ 
Not applicable ☐ 
 
Is cold preservation fluid, iv giving set 
and a bowl of ice ready? 
Yes ☐ 
 
Is a scalpel ready for decannulation? 
Yes ☐ 
 
 
 
Name of perfusionist: 
 
Signature: 
 
Date/time: 
 
End of procedure 
Has the instrument, swab, and needle 
count been completed and correct? 
Yes ☐ 
 
Has the EVNP assessment score been 
completed? 
Yes ☐ 
 
Has all paperwork been completed? 
Yes ☐ 
 
Has the perfusionist handed over to 
the implanting surgeon? 
Yes ☐ 
 
Have the specimens been labelled? 
Yes ☐ 
 
Were there any technical problems? 
No ☐ 
Yes ☐ ______________________ 
 
Debrief – what went well, what could 
be improved next time? 
 
 
 
 
 
 
Figure 2: Checklist used before, during, and after EVNP in centre 1. N/A – not applicable 

 
